113 related articles for article (PubMed ID: 2939691)
1. Comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients. Biochemical aspects.
Nyström C; Ross SB; Hällström T; Kelder D
Acta Psychiatr Scand; 1986 Feb; 73(2):133-8. PubMed ID: 2939691
[TBL] [Abstract][Full Text] [Related]
2. Comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients. A cross-over study.
Nyström C; Hällström T
Acta Psychiatr Scand; 1987 Apr; 75(4):377-82. PubMed ID: 3035878
[TBL] [Abstract][Full Text] [Related]
3. Double-blind comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients. Clinical aspects.
Nyström C; Hällström T
Acta Psychiatr Scand; 1985 Jul; 72(1):6-15. PubMed ID: 2930998
[TBL] [Abstract][Full Text] [Related]
4. Effects of zimelidine and desipramine on serotonin and noradrenaline uptake mechanisms in relation to plasma concentrations and to therapeutic effects during treatment of depression.
Aberg-Wistedt A; Jostell KG; Ross SB; Westerlund D
Psychopharmacology (Berl); 1981; 74(4):297-305. PubMed ID: 6457309
[TBL] [Abstract][Full Text] [Related]
5. Serotonin reuptake inhibition vs. norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives.
Emrich HM; Berger M; Riemann D; von Zerssen D
Pharmacopsychiatry; 1987 Mar; 20(2):60-3. PubMed ID: 3108909
[TBL] [Abstract][Full Text] [Related]
6. A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. II. Biochemical findings.
Aberg-Wistedt A; Ross SB; Jostell KG; Sjöquist B
Acta Psychiatr Scand; 1982 Jul; 66(1):66-82. PubMed ID: 6181652
[TBL] [Abstract][Full Text] [Related]
7. Maprotiline in the treatment of endogenous depression: comparison of therapeutic effect with serotonin level in blood platelets.
Mück-Seler D; Deanović Z; Jamnicky B; Jakupcević M; Mihovilović M
Psychopharmacology (Berl); 1983; 79(2-3):262-5. PubMed ID: 6189139
[TBL] [Abstract][Full Text] [Related]
8. A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients.
Timmerman L; de Beurs P; Tan BK; Leijnse-Ybema H; Sanchez C; Høpfner Petersen HE; Cohen Stuart MH
Int Clin Psychopharmacol; 1987 Jul; 2(3):239-53. PubMed ID: 2447151
[TBL] [Abstract][Full Text] [Related]
9. Plasma 3,4-dihydroxyphenylethyleneglycol and therapeutic response to maprotiline and indalpine in major depression.
Lôo H; Benkelfat C; Poirier MF; Vanelle JM; Olié JP; Dennis T; Scatton B
Neuropsychobiology; 1986; 15(2):62-7. PubMed ID: 3762900
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of serotonin and noradrenaline uptake in human plasma after withdrawal of zimelidine and clomipramine treatment.
Ross SB; Aberg-Wistedt A
Psychopharmacology (Berl); 1983; 79(4):298-303. PubMed ID: 6222388
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of maprotiline and zimelidine and their relationship to clinical response in depressed patients.
Hrdina PD; Lapierre YD
Ther Drug Monit; 1986; 8(4):400-6. PubMed ID: 2950616
[TBL] [Abstract][Full Text] [Related]
12. Clinical trials with new bicyclic and tetracyclic compounds: zimelidine and maprotiline [proceedings].
Claghorn JL; Mathew RJ
Psychopharmacol Bull; 1981 Jan; 17(1):23-6. PubMed ID: 6453355
[No Abstract] [Full Text] [Related]
13. Zimelidine vs maprotiline in depressed outpatients. A preliminary report.
d'Elia G; Hällström T; Nyström C; Ottosson JO
Acta Psychiatr Scand Suppl; 1981; 290():225-35. PubMed ID: 6452793
[TBL] [Abstract][Full Text] [Related]
14. Urinary 3-methoxy, 4-hydroxyphenylethylene glycol and therapeutic response to maprotiline and indalpine in major depression.
Loo H; Benkelfat C; Vanelle JM; Dennis T; Poirier MF; Olie JP; Scatton B
J Neural Transm; 1986; 66(1):47-58. PubMed ID: 3734775
[TBL] [Abstract][Full Text] [Related]
15. Plasma free 3-methoxy-4-hydroxyphenylglycol predicts response to fluoxetine.
Ko HC; Lu RB; Shiah IS; Hwang CC
Biol Psychiatry; 1997 Apr; 41(7):774-81. PubMed ID: 9084896
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone suppression test and the response to antidepressant depending on their central monoaminergic action in major depression.
Benkelfat C; Poirier MF; Léouffre P; Gay C; Löo H
Can J Psychiatry; 1987 Apr; 32(3):175-8. PubMed ID: 3471304
[TBL] [Abstract][Full Text] [Related]
17. Recent advances with zimeldine, the 5-HT reuptake blocker, in the treatment of depression. Proceedings of a symposium. Laxenburg, Austria, July 9, 1983.
Acta Psychiatr Scand Suppl; 1983; 308():1-199. PubMed ID: 6230882
[No Abstract] [Full Text] [Related]
18. Plasma tryptophan and tyrosine ratios to competing amino acids in relation to antidepressant response to citalopram and maprotiline. A preliminary study.
Møller SE; de Beurs P; Timmerman L; Tan BK; Leijnse-Ybema HJ; Stuart MH; Petersen HE
Psychopharmacology (Berl); 1986; 88(1):96-100. PubMed ID: 3080781
[TBL] [Abstract][Full Text] [Related]
19. Zimeldine versus nomifensine. A double-blind study of depressed inpatients.
Knudsen P; Bjørndal N; Johnsen T; Pfeiffer Petersen K
Neuropsychobiology; 1984; 11(4):236-42. PubMed ID: 6238240
[TBL] [Abstract][Full Text] [Related]
20. Toward a biochemical classification of depressive disorders. III: Pretreatment urinary MHPG levels as predictors of response to treatment with maprotiline.
Schatzberg AF; Rosenbaum AH; Orsulak PJ; Rohde WA; Maruta T; Kruger ER; Cole JO; Schildkraut JJ
Psychopharmacology (Berl); 1981; 75(1):34-8. PubMed ID: 6795656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
